PTC Therapeutics, Inc. Proceeds from Sale of Available-for-sale Securities
PTC Therapeutics, Inc. (PTCT) reported Proceeds from Sale of Available-for-sale Securities of $392.09 million for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-04.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities · last filed 2021-05-04
- PTC Therapeutics, Inc. proceeds from sale of available-for-sale securities for the quarter ending 2021-03-31 was $392.09M, a 74.27% increase year-over-year.
- PTC Therapeutics, Inc. proceeds from sale of available-for-sale securities for the quarter ending 2020-03-31 was $225.00M.
| Period end | Proceeds from Sale of Available-for-sale Securities 3 month |
|---|---|
| 2021-03-31 | $392.09M 10-Q · filed 2021-05-04 |
| 2020-03-31 | $225.00M 10-Q · filed 2021-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |